Cancer immunotherapy

ADC Therapeutics Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma

Retrieved on: 
Thursday, February 4, 2021
Biotechnology, Health, Oncology, Clinical trials, Cancer treatments, Clinical medicine, Drugs, Antibody-drug conjugates, Antineoplastic drugs, Orphan drugs, Cancer immunotherapy, Camidanlumab tesirine, Breakthrough therapy, Pembrolizumab, Loncastuximab tesirine, Genmab, Camidanlumab Tesirine (Cami), ADC Therapeutics

At the 62nd American Society of Hematology (ASH) Annual Meeting, the Company presented preliminary Phase 2 data consistent with Phase 1 results.

Key Points: 
  • At the 62nd American Society of Hematology (ASH) Annual Meeting, the Company presented preliminary Phase 2 data consistent with Phase 1 results.
  • For more information about the Phase 2 clinical trial of Cami, please visit https://clinicaltrials.gov/ (identifier NCT04052997).
  • Cami is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma (HL), as well as in a Phase 1a/1b clinical trial in patients with relapsed or refractory HL and non-Hodgkin lymphoma and a Phase 1b clinical trial as monotherapy and in combination with pembrolizumab in solid tumors.
  • Camidanlumab tesirine (Cami, formerly ADCT-301), the Companys second lead product candidate, is being evaluated in a 117-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma (HL) for which preliminary data have demonstrated an 83% ORR, consistent with the Phase 1 clinical trial.

BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

Retrieved on: 
Thursday, February 4, 2021
Clinical medicine, Life sciences, Medicine, Biotechnology, Immunotherapy, Virotherapy, Tumor microenvironment, Cancer immunotherapy, Checkpoint inhibitor, Biopharmaceutical

ASCO GU is being held from Thursday, February 11, 2021 to Saturday, February 13, 2021.

Key Points: 
  • ASCO GU is being held from Thursday, February 11, 2021 to Saturday, February 13, 2021.
  • BXCL701 is an investigational orally administered innate immune activator designed to initiate inflammation in the tumor microenvironment.
  • BTI's preclinical data supports BXCL701's synergy with both current checkpoint inhibitor-based therapies and emerging immunotherapies directed to activate T-cells, such as IL-2.
  • BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.

ThermoGenesis Holdings Launches a GMP Compliant Automated Cell Washing and Reformulation System -- PXP™-LAVARE -- for CAR-T Manufacturing

Retrieved on: 
Wednesday, February 3, 2021
Clinical medicine, Medicine, Gene therapy, Immune system, Cancer immunotherapy, Chimeric antigen receptor T cell, Lymphoma, Branches of biology

The PXP-LAVARE is a GMP compliant automated cell processing system and allows for fast, automated, and reliable washing and reformation of cell suspensions.

Key Points: 
  • The PXP-LAVARE is a GMP compliant automated cell processing system and allows for fast, automated, and reliable washing and reformation of cell suspensions.
  • The PXP-LAVARE system is an optional cell reformation accessory designed for use along with the PXP-1000 System, a U.S. FDA-cleared 510(k) class II medical device that is used for downstream cGMP compliant clinical manufacturing of cell-based therapeutics, such as chimeric antigen receptor-T (CAR-T) cells.
  • "We continue to develop and improve upon our broad line of automated cell processing tools to address the rapid growth of the cell and gene therapy market," said Chris Xu, PhD, Chief Executive Officer of ThermoGenesis.
  • ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies.

PDS Biotech Announces Preliminary Efficacy Achievement in Phase 2 Combination Trial of PDS0101 Led by the National Cancer Institute

Retrieved on: 
Wednesday, February 3, 2021
Clinical medicine, Cancer treatments, Medicine, Antineoplastic drugs, Head and neck cancer, Otorhinolaryngology, Pembrolizumab, Cancer immunotherapy, Cervical cancer, National Cancer Institute, Merck & Co., Cancer

The NCI Center for Cancer Researchs Laboratory of Tumor Immunology and Biology (LTIB) and Genitourinary Malignancies Branch (GMB) are jointly leading this Phase 2 trial.

Key Points: 
  • The NCI Center for Cancer Researchs Laboratory of Tumor Immunology and Biology (LTIB) and Genitourinary Malignancies Branch (GMB) are jointly leading this Phase 2 trial.
  • Pooled data from phase 1 and 2 trials reported in the October 2020 issue of the Journal for Immunotherapy of Cancer (J ImmunoTher Cancer 2020;8:e001395.
  • In partnership with Merck and Co., PDS Biotech is studying a combination of PDS0101 and KEYTRUDA to a Phase 2 study in first-line treatment of recurrent or metastatic head and neck cancer.
  • In separate partnership with the National Cancer Institute (NCI), and The University of Texas MD Anderson Cancer Center, PDS Biotech is conducting additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer respectively.

GEMoaB Announces UniCAR-T-CD123 Data from its Ongoing Phase I Study in Patients with Relapsed/Refractory AML (rrAML) to be Presented at Virtual 3rd EHA-EBMT European CAR T-Cell Meeting

Retrieved on: 
Wednesday, February 3, 2021
Clinical medicine, Cancer immunotherapy, Medicine, Branches of biology, Leukemia, Lymphoma, Virotherapy, Immunotherapy, Tumors of the hematopoietic and lymphoid tissues, Chimeric antigen receptor T cell, GEMoaB Monoclonals

"We are highly encouraged by the fact that UniCAR-T-CD123 has demonstrated a favorable safety and efficacy profile in rrAML.

Key Points: 
  • "We are highly encouraged by the fact that UniCAR-T-CD123 has demonstrated a favorable safety and efficacy profile in rrAML.
  • The clinical data nicely confirm our UniCAR key platform claims and provide the clinical proof of UniCAR's rapid switch on/off and re-activation capability.
  • We look forward to progressing our study and positioning UniCAR as a potentially superior cellular immunotherapy platform for patients with hard-to-treat advanced hematologic malignancies and solid tumors."
  • Phase IA dose-finding studies of the first UniCAR assets UniCAR-T-CD123 in hematological malignancies and UniCAR-T-PSMA in solid tumors are currently recruiting patients.

GEMoaB Announces UniCAR-T-CD123 Data from its Ongoing Phase I Study in Patients with Relapsed/Refractory AML (rrAML) to be Presented at Virtual 3rd EHA-EBMT European CAR T-Cell Meeting

Retrieved on: 
Wednesday, February 3, 2021
Clinical medicine, Cancer immunotherapy, Medicine, Branches of biology, Leukemia, Lymphoma, Virotherapy, Immunotherapy, Tumors of the hematopoietic and lymphoid tissues, Chimeric antigen receptor T cell, GEMoaB Monoclonals

"We are highly encouraged by the fact that UniCAR-T-CD123 has demonstrated a favorable safety and efficacy profile in rrAML.

Key Points: 
  • "We are highly encouraged by the fact that UniCAR-T-CD123 has demonstrated a favorable safety and efficacy profile in rrAML.
  • The clinical data nicely confirm our UniCAR key platform claims and provide the clinical proof of UniCAR's rapid switch on/off and re-activation capability.
  • We look forward to progressing our study and positioning UniCAR as a potentially superior cellular immunotherapy platform for patients with hard-to-treat advanced hematologic malignancies and solid tumors."
  • Phase IA dose-finding studies of the first UniCAR assets UniCAR-T-CD123 in hematological malignancies and UniCAR-T-PSMA in solid tumors are currently recruiting patients.

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

Retrieved on: 
Wednesday, February 3, 2021
Clinical medicine, Medicine, Medical specialties, Cancer immunotherapy, Laboratoires Servier, Immunotherapy, Innovative Medicines Initiative, Cancer

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).

Key Points: 
  • THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
  • Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.
  • The clinical development of engineered T-cell treatments is moving ahead and the EU has already approved this therapy for the treatment of leukemia.
  • T2EVOLVE includes innovators and pioneers in the field of immunotherapy from 9 nations and is coordinated by the Universittsklinikum Wrzburg, Germany, and Servier, France.

United States Non-Small Cell Lung Cancer Market Landscape Report 2021-2025: Pipeline Products, Epidemiology, Market Valuations, Drug Sales & Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 2, 2021
Health, Oncology, Clinical medicine, Medicine, Cancer treatments, Carcinoma, Small-cell carcinoma, Lung cancer, Cancer, Epidemiology of cancer, Chemotherapy, Treatment of lung cancer, Cancer immunotherapy

The "US Non-Small Cell Lung Cancer Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Non-Small Cell Lung Cancer Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Non-Small Cell Lung Cancer Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Non-Small Cell Lung Cancer pipeline products, Non-Small Cell Lung Cancer epidemiology, Non-Small Cell Lung Cancer market valuations and forecast, Non-Small Cell Lung Cancer drugs sales and competitive landscape in the US.
  • Non-Small Cell Lung Cancer pipeline: Find out the products in clinical trials for the treatment of Non-Small Cell Lung Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Non-Small Cell Lung Cancer epidemiology: Find out the number of patients diagnosed (prevalence) with Non-Small Cell Lung Cancer in the US
    Non-Small Cell Lung Cancer drugs: Identify key products marketed and prescribed for Non-Small Cell Lung Cancer in the US, including trade name, molecule name, and company
    Non-Small Cell Lung Cancer drugs sales: Find out the sales revenues of Non-Small Cell Lung Cancer drugs in the US
    Non-Small Cell Lung Cancer market valuations: Find out the market size for Non-Small Cell Lung Cancer drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Non-Small Cell Lung Cancer drugs market share: Find out the market shares for key Non-Small Cell Lung Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Non-Small Cell Lung Cancer products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005914/en/

Immunomic Therapeutics’ CEO to present at the BIO CEO & Investor Digital Conference

Retrieved on: 
Tuesday, February 2, 2021
Oncology, Health, Infectious diseases, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Cancer, Medical specialties, Clinical medicine, Brain tumor, Oncology, Cancer immunotherapy, Glioblastoma, GBM, UNITE, Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the BIO CEO & Investor Digital Conference, February 16-18, 2021.

Key Points: 
  • Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the BIO CEO & Investor Digital Conference, February 16-18, 2021.
  • Chief Executive Officer at ITI, Dr. Bill Hearl, will present a talk titled, ITI-1000-A Novel Immunotherapy for GBM.
  • Dr. Hearl will discuss ITIs investigational UNiversal Intracellular Targeted Expression (UNITE) platform and its application in immuno-oncology, specifically glioblastoma multiforme (GBM).
  • This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases.

Oncocyte Announces Definitive Agreement to Acquire Chronix Biomedical, Inc.

Retrieved on: 
Tuesday, February 2, 2021
Clinical medicine, Medicine, Branches of biology, Cancer immunotherapy, Biotechnology, Medical genetics, Immunotherapy, Virotherapy, Molecular diagnostics, Treatment of cancer, Organ transplantation

Under the agreement, which supersedes the previous collaboration agreement between the companies announced in October 2020, Oncocyte will acquire the intellectual property (IP) and technology for Chronixs TheraSure-CNI Monitor, a patented, blood-based test for immune-therapy monitoring, as well as the IP for Chronixs organ transplant technology.

Key Points: 
  • Under the agreement, which supersedes the previous collaboration agreement between the companies announced in October 2020, Oncocyte will acquire the intellectual property (IP) and technology for Chronixs TheraSure-CNI Monitor, a patented, blood-based test for immune-therapy monitoring, as well as the IP for Chronixs organ transplant technology.
  • The initial focus will be on clinical studies in lung cancer and other solid tumor types treated by immunotherapy.
  • Chronix Biomedical, Inc. is aprivately held, U.S.-based molecular diagnostics company developing blood tests for use in cancer treatment and organ transplantation.
  • Chronix Biomedical has operations in theU.S.&Germany, and the commercial launch of their products began in the EU in 2018.